XPO1 and diffuse large B-cell lymphoma: Selinexor, an inhibitor of the nuclear export protein Exportin 1 (XPO-1), has been investigated in an open-label phase 2b study, the “SADAL” trial, as a single agent for R/R DLBCL after two lines of treatment, where it showed an ORR of 28% (with 11% CR) [103].